Monte Rosa Therapeutics, Inc. has been removed from NASDAQ Biotechnology Index.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.91 USD | +10.88% | +5.45% | +2.65% |
04:37pm | UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating | MT |
Mar. 14 | Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.65% | 268M | |
+2.59% | 42.75B | |
+47.70% | 41.61B | |
+12.21% | 41.34B | |
-8.83% | 26.59B | |
+7.92% | 25.49B | |
-22.51% | 18.12B | |
+31.23% | 12.24B | |
-1.47% | 11.76B | |
+8.57% | 11B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics, Inc.(NasdaqGS: GLUE) dropped from NASDAQ Biotechnology Index